So despite the success of HIV drugs and PrEP, precarious health-care systems and high drug costs mean we can't rely on them ...

The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th International AIDS Conference on HIV Science (IAS 2025), have raised an alarm ...

The global hunt for an HIV cure remains a puzzle, despite nearly 40 years of research and progress in treatment and prevention. Scientists have struggled largely because of the virus's ability ...

In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...

How will the Trump administration's cuts to HIV research impact the progress that's been made towards ending the epidemic in the U.S.?

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

Global Fund notes that the US has contributed more than $26.31 billion to date and pledged up to $6 billion for the Seventh ...